drugset / Trial / NCT00002787
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
Phase 1
Completed
22 enrolled
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor. There is no guarantee or promise that this procedure will be successful
Timeline
- Start
- 1996-03
- Primary completion
- 2002-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | autologous immunoglobulin idiotype-KLH conjugate vaccine | Vaccine | — | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | — | Subcutaneous |